Uniqure jumps after FDA vaccines chief Vinay Prasad to step down

U.S.-listed shares of Dutch drugmaker UniQure UQ1.F, QURE.O rise 61% to $22.95 in extended trading

The head of the U.S. Food and Drug Administration's vaccines and biologics unit, Dr. Vinay Prasad, will leave the agency at the end of April, FDA commissioner Marty Makary said on Friday

More recently, Prasad's division at the FDA has been mired in a back and forth with Dutch drugmaker UniQure over its gene therapy for Huntington's disease

Co is developing a gene therapy, AMT-130, for Huntington’s disease, a rare condition that affects motor function

Makary says in a post on X that a successor will be named before Prasad’s departure

Shares of some gene therapy developers also rose in extended trading, following the announcement

Shares of Sarepta Therapeutics SRPT.O rises 6%, Capricor Therapeutics CAPR.O climbs 12%, Taysha Gene Therapies TSHA.O gains 1%

UniQure rose 35.5% in 2025